登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
ClinicalTrials.gov 上登记的一项IgA 肾病开放试验,由四川省人民医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06676007,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Primary IgA nephropathy diagnosed by renal biopsy within 3 months
入选标准第 2 条
Patients who have received systemic immunosuppressive drug treatment within 3 months prior to enrollment
排除标准第 12 条
Patients who have received any systemic GCS treatment within the past 3 months prior to enrollment
排除标准第 13 条
Current or previous (within the past 2 years) alcoholism or drug abuse;
排除标准第 15 条
eGFR≥30ml/min/1.73m2
入选标准第 3 条
Patients diagnosed with malignant tumors within the past 5 years
排除标准第 8 条
During the study treatment period and 3-month follow-up period, women who are pregnant, breastfeeding, or unwilling to use highly effective contraception (contraception is only required for women with fertility potential)
排除标准第 17 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06676007,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Target patients aged 18-75, including those aged 18 and 75 Primary IgA nephropathy diagnosed by renal biopsy within 3 months eGFR≥30ml/min/1.73m2 24-hour urine protein ≥ 1.0g/d, or UPCR ≥ 0.8 g/g Sign informed consent排除标准:Exclusion Criteria:
Including but not limited to secondary IgAN caused by allergic purpura, systemic lupus erythematosus, cirrhosis, rheumatoid arthritis, and ankylosing spondylitis Patients who have received kidney transplantation or dialysis Patients with other glomerular diseases (such as C3 glomerular disease and/or diabetes nephropathy) and nephrotic syndrome (i.e. proteinuria>3.5 g/d, serum albumin<3.0 g/dl, with or without edema) Patients with acute, chronic, or potential infectious diseases, including hepatitis, tuberculosis, human immunodeficiency virus, and chronic urinary tract infections Patients with type 1 or type 2 diabetes diagnosed and poorly controlled (HbA1c>8%) Patients with a history of unstable angina, grade III or IV congestive heart failure, and/or clinically significant arrhythmias Patients with poor blood pressure control (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg) Patients diagnosed with malignant tumors within the past 5 years Patients with known glaucoma, known cataracts, and/or a history of cataract surgery Gastrointestinal diseases that may interfere with the study of drug efficacy or release, such as peptic ulcer disease, inflammatory bowel disease, and chronic diarrhea Patients with severe adverse reactions to steroids in the past, including psychiatric symptoms Patients who have received systemic immunosuppressive drug treatment within 3 months prior to enrollment Patients who have received any systemic GCS treatment within the past 3 months prior to enrollment Patients taking potent cytochrome P450 3A4 inhibitors (CYP3A4) Current or previous (within the past 2 years) alcoholism or drug abuse; Expected lifespan<5 years During the study treatment period and 3-month follow-up period, women who are pregnant, breastfeeding, or unwilling to use highly effective contraception (contraception is only required for women with fertility potential) Researchers believe that patients who are not suitable for treatment with Nefecon
引自 ClinicalTrials.gov, NCT06676007, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06676007,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。